Anlon Healthcare Limited has successfully secured shareholder approval for its strategic shift in IPO fund utilization, with an overwhelming majority voting in favor of reallocating ₹2,332.69 lakhs from capital expenditure to strategic acquisitions. The postal ballot concluded on January 7, 2026, marking a significant milestone in the company's growth strategy.

Voting Results Overview

The postal ballot results demonstrate strong shareholder confidence in the company's strategic direction:

Strategic Fund Reallocation Details

The approved resolution allows Anlon Healthcare to redirect funds originally planned for greenfield expansion towards strategic acquisitions:

Postal Ballot Process

The voting process was conducted entirely through electronic means, with Mr. Keyur Ghelani of M/s. K. P. Ghelani and Associates serving as the scrutinizer. The e-voting facility was provided by Kfin Technologies Limited, ensuring transparency and compliance with regulatory requirements.

Strategic Benefits

The approved strategy shift from greenfield to brownfield investment offers several advantages:

• Immediate Capacity Addition: Access to validated production lines and established systems
• Time Efficiency: Avoiding longer timelines associated with new facility construction
• Early Revenue Generation: Faster monetization of acquired assets
• Operational Synergies: Leveraging existing regulatory approvals and trained workforce

Financial Impact

The reallocation represents a significant portion of the company's IPO proceeds:

With this overwhelming shareholder approval, Anlon Healthcare can now proceed with its planned acquisitions of Bizotic Lifescience Private Limited and Apiqo Organics Private Limited, positioning the company for accelerated growth through strategic inorganic expansion.

Anlon Healthcare Limited has announced a strategic move to strengthen its position in the pharmaceutical intermediates market. The company has entered into a Share Purchase Agreement (SPA) to acquire a controlling stake in Apiqo Organics Private Limited, a move that aims to enhance its vertical integration and manufacturing capabilities.

Key Acquisition Details

Strategic Implications

The acquisition of Apiqo Organics is expected to bring several strategic benefits to Anlon Healthcare:

1. Vertical Integration: The move aims to enhance Anlon's vertical integration, potentially improving its supply chain efficiency and cost structure.

2. Manufacturing Capacity: The deal is set to add an additional 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates to Anlon's portfolio.

3. Supply Security: By acquiring Apiqo, Anlon seeks to secure a critical supply of high-quality intermediates, which could lead to more reliable production processes.

4. Market Position: The acquisition is expected to strengthen Anlon's position as a more agile, cost-competitive, and reliable partner for both innovator and generic pharmaceutical companies worldwide.

About Apiqo Organics

Apiqo Organics Private Limited, formerly known as M/s Apple Life Science, is engaged in manufacturing pharmaceutical intermediates, industrial and fine chemicals, and inorganic chemicals. The company was incorporated on December 1, 2025, following its conversion from a partnership firm to a private limited company.

Financial Snapshot of Apiqo Organics

Transaction Timeline

The acquisition is subject to customary closing conditions as outlined in the SPA. It is expected to be completed within three months from the date of signing the agreement, or as mutually agreed upon by the parties involved.

Regulatory Compliance

This disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The strategic acquisition by Anlon Healthcare demonstrates the company's commitment to growth and its focus on strengthening its position in the pharmaceutical intermediates market. By securing a critical supply chain component and expanding its manufacturing capabilities, Anlon aims to better serve the global pharmaceutical industry's needs.